SCHEMBL3337347

SCHEMBL3337347

O=C1CC[C@H](NC(=O)OCc2ccccc2)C(NC(=O)OCc2ccccc2)C1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.56
GAA P10253 1/20 0.56
CPB1 P15086 2/20 0.54
TSHR P16473 1/20 0.53
CYP3A4 P08684 1/20 0.52
CYP2C9 P11712 1/20 0.52
CYP2C19 P33261 1/20 0.52
TLR4 O00206 1/20 0.50
EPHX1 P07099 1/20 0.50
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
ACHE P22303 1/20 0.49
CTSL P07711 1/20 0.48
CTSB P07858 1/20 0.48
CTSK P43235 1/20 0.48
NAAA Q02083 1/20 0.47
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4083309 1.00 ALDH1A1 (0.56) ALDH1A1GAACPB1TSHRCYP3A4
SCHEMBL4083307 1.00 ALDH1A1 (0.56) ALDH1A1GAACPB1TSHRCYP3A4
SCHEMBL3337341 1.00 ALDH1A1 (0.56) ALDH1A1GAACPB1TSHRCYP3A4
SCHEMBL4356664 0.96 ALDH1A1 (0.52) ALDH1A1GAACPB1TSHRCYP3A4
SCHEMBL4356663 0.96 ALDH1A1 (0.52) ALDH1A1GAACPB1TSHRCYP3A4
SCHEMBL12035392 0.94 CPB1 (0.52) ALDH1A1GAACPB1TSHRCYP3A4
SCHEMBL13823476 0.90 CPB1 (0.53) ALDH1A1GAACPB1TSHRCYP3A4
SCHEMBL12668212 0.90 CPB1 (0.56) ALDH1A1GAACPB1TSHRCYP3A4
SCHEMBL13668185 0.89 ALDH1A1 (0.46) ALDH1A1GAACPB1TSHRCYP3A4
SCHEMBL10915487 0.86 CPB1 (0.68) ALDH1A1GAACPB1TSHRCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1577301-B1 Antithrombotic diaminocyclohexane derivatives DAIICHI SANKYO CO LTD (JP) 2012-09-12 EP disclosed
US-20100099660-A1 METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2010-04-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099660-A1 METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES F2, PLAT, MPL ALDH1A1 3214/4885GAA 1144/4885CPB1 507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.